olivLaw · US equity research
4D Molecular Therapeutics, Inc. FDMT
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
4D Molecular Therapeutics is a late-stage biotechnology company developing genetic therapies built on proprietary AAV vectors, focused on 4D-150 for wet age-related macular degeneration and diabetic macular edema. It matters now because its Phase 3 program is underway with topline readouts expected in 2027, and it reported 430.6 mn USD in cash and equivalents at June 30, 2026.
At the close of 04 Nov 2026, 4D Molecular Therapeutics, Inc. (FDMT) stock was 12.28 USD (+2.76% on the day), with market capitalisation 611.3 m USD, beta 1.38, 52-week range 7.19–16.76 USD. Latest reported quarter (Q2 2026): revenue of 3.8 m USD (+25,106.7% YoY), net income of -72.9 m USD, diluted EPS -1.04 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 48.0
- neutral
- Bollinger (20, 2)
- 10.95 – 13.60
- in the upper half of the band · %B 0.50 · band width 21.6%
- SMA 50 / 200
- 13.49 / 10.94
- mixed trend
- MACD (12, 26, 9)
- -0.40 / -0.45
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −5.0% | −2.0% | −3.0 pp | — |
| 3 months | +19.5% | −2.2% | +21.6 pp | — |
| 6 months | +17.9% | +4.3% | +13.6 pp | — |
| Year to date | +63.7% | +10.6% | +53.2 pp | — |
| 1 year | +14.2% | +10.5% | +3.8 pp | −3.8% |
| 3 years | +5.9% | +73.7% | −67.8 pp | +18.6% |
| 5 years | −50.3% | +61.7% | −112.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0 k | 1.0 k | 14.0 k | 15.0 k | 90.0 k | 85.1 m | 3.0 m | 3.8 m |
| Operating income | -51.1 m | -56.1 m | -53.6 m | -59.5 m | -61.2 m | 14.7 m | -73.6 m | -77.0 m |
| Depreciation & amortisation | 1.2 m ≈ | 1.1 m | 1.1 m | 1.2 m ≈ | 1.3 m ≈ | 1.2 m | 1.3 m | 1.3 m ≈ |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -43.8 m | -49.7 m | -48.0 m | -54.7 m | -56.9 m | 19.4 m | -68.8 m | -72.9 m |
| Diluted EPS | -0.79 | -0.89 ≈ | -0.86 | -0.98 | -1.01 | 0.30 ≈ | -1.01 | -1.04 |
| Operating cash flow | -29.4 m ≈ | -45.9 m | -47.8 m | -43.4 m ≈ | -46.5 m ≈ | 28.6 m | -68.1 m | -70.0 m ≈ |
| Capex | 1.8 m ≈ | 949.0 k | 631.0 k | 66.0 k ≈ | -91.0 k ≈ | -70.0 k | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 7.0 m | 13.6 m | 18.0 m | 3.1 m | 20.7 m | 37.0 k | 85.2 m |
| Revenue YoY | unavailable | +94.8% | +32.5% | −82.7% | +562.3% | −99.8% | +230,194.6% |
| Net income | -49.3 m | -56.7 m | -71.3 m | -107.5 m | -100.8 m | -160.9 m | -140.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -705.8% | -416.5% | -395.4% | -3,435.4% | -486.6% | -434,778.4% | -164.4% |
| Free cash flow | -39.9 m | -51.9 m | -78.2 m | -98.2 m | -78.6 m | -138.4 m | -109.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 60.2 m USD
- Financial debt
- 0 USD
- Net debt
- -60.2 m USD
- Equity
- 505.7 m USD
- Total assets
- 566.7 m USD
- Debt / equity
- 0.00x
- Current ratio
- 9.39x
- ROE
- -27.6%
- ROA
- -24.9%
- FCF margin
- -128.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 13.6 m | 18.0 m | 3.1 m | 20.7 m | 37.0 k | 85.2 m | SEC (XBRL)· 18 Mar 2026verified |
| Operating income | -56.7 m | -71.3 m | -110.0 m | -112.9 m | -187.8 m | -159.5 m | SEC (XBRL)· 18 Mar 2026verified |
| Depreciation & amortisation | 1.4 m | 1.5 m | 2.4 m | 4.2 m | 4.7 m | 4.7 m | SEC (XBRL)· 18 Mar 2026verified |
| EBITDA | -55.2 m ≈ | -69.8 m ≈ | -107.6 m ≈ | -108.7 m ≈ | -183.2 m ≈ | -154.9 m ≈ | SEC (XBRL)· 18 Mar 2026derived |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 18 Mar 2026verified |
| Net income | -56.7 m | -71.3 m | -107.5 m | -100.8 m | -160.9 m | -140.1 m | SEC (XBRL)· 18 Mar 2026verified |
| Diluted EPS | — | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 | SEC (XBRL)· 18 Mar 2026verified |
| Weighted average diluted shares | — | 27.7 m | 32.4 m | 39.1 m | 53.9 m | 57.9 m | SEC (XBRL)· 18 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 276.7 m | 153.0 m | 52.4 m | 249.1 m | 149.3 m | 60.2 m | SEC (XBRL)· 18 Mar 2026verified |
| Receivables | 1.5 m | 47.0 k | 0 | — | — | — | SEC (XBRL)· 15 Mar 2023verified |
| Current assets | 282.7 m | 256.3 m | 220.5 m | 296.6 m | 434.9 m | 413.1 m | SEC (XBRL)· 18 Mar 2026verified |
| Property, plant & equipment, net | 5.1 m | 14.4 m | 22.3 m | 20.1 m | 19.5 m | 14.9 m | SEC (XBRL)· 18 Mar 2026verified |
| Total assets | 288.3 m | 353.5 m | 261.8 m | 339.9 m | 560.4 m | 566.7 m | SEC (XBRL)· 18 Mar 2026verified |
| Accounts payable | 1.8 m | 4.8 m | 3.3 m | 3.5 m | 4.4 m | 11.2 m | SEC (XBRL)· 18 Mar 2026verified |
| Long-term debt | — | — | — | — | — | 0 | SEC (XBRL)· 13 Aug 2026verified |
| Current liabilities | 16.7 m | 16.3 m | 15.7 m | 19.0 m | 29.1 m | 44.0 m | SEC (XBRL)· 18 Mar 2026verified |
| Total liabilities | 31.9 m | 34.4 m | 30.5 m | 32.1 m | 49.8 m | 61.0 m | SEC (XBRL)· 18 Mar 2026verified |
| Equity | 256.4 m † | 319.1 m † | 231.3 m † | 307.8 m † | 510.6 m † | 505.7 m † | SEC (XBRL)· 18 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -50.9 m | -69.1 m | -86.7 m | -75.8 m | -134.6 m | -109.1 m | SEC (XBRL)· 18 Mar 2026verified |
| Capex | 1.0 m | 9.1 m | 11.5 m | 2.8 m | 3.8 m | 536.0 k | SEC (XBRL)· 18 Mar 2026verified |
| Free cash flow | -51.9 m ≈ | -78.2 m ≈ | -98.2 m ≈ | -78.6 m ≈ | -138.4 m ≈ | -109.6 m ≈ | SEC (XBRL)· 18 Mar 2026derived |
| Investing cash flow | -1.0 m | -172.7 m | -17.1 m | 115.7 m | -302.4 m | -93.0 m | SEC (XBRL)· 18 Mar 2026verified |
| Financing cash flow | 279.0 m | 118.1 m | 3.1 m | 156.8 m | 337.3 m | 113.0 m | SEC (XBRL)· 18 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 37.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 611.3 m USD
Key indicators
Coverage and freshness
Score by group
38% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -46.4% | 33 (vs peers) | 28% |
| Net margin · Quality | -194.7% | 45 (vs peers) | 17% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 200.9% | 100 (on a fixed band) | 22% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 8.0x | 100 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -25.5% | 0 (on a fixed band) | 22% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality38/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
4D Molecular Therapeutics, Inc. (FDMT). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 85.2 m USD in 2025; YoY growth 230,194.6%; net margin -194.7%; ROE -43.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 200.9%
- Current ratio: 8.0x
What contradicts it
- FCF yield: -25.5%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 249.4 bn | 28.7 | 91.5% | 23.0% | +10.0% | +34% / +71% |
| GILDGilead Sciences, Inc. | 207.7 bn | — | -22.3% | -12.5% | +2.4% | +33% / +119% |
| MRNAModerna, Inc. | 91.2 bn | — | -39.0% | -141.4% | −39.9% | +779% / +194% |
| RVMDRevolution Medicines, Inc. | 41.6 bn | — | -79.1% | — | unavailable | +150% / +733% |
| BIIBBiogen Inc. | 36.8 bn | 106.4 | 1.9% | 3.4% | +2.2% | +37% / +6% |
| MESOMesoblast Limited | 18.5 bn | — | -19.0% | -593.9% | +191.4% | −17% / +425% |
| EXELExelixis, Inc. | 17.6 bn | 21.6 | 44.3% | 35.5% | +7.0% | +64% / +232% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| TWSTTwist Bioscience Corporation | 8.9 bn | — | -29.6% | -31.7% | +20.3% | +345% / +493% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +51% / unavailable |
| TARSTarsus Pharmaceuticals, Inc. | 3.4 bn | — | -319.8% | -102.9% | +146.7% | −14% / +318% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| ADMAAdma Biologics, Inc. | 2.3 bn | 14.9 | 41.9% | 33.0% | +19.6% | −45% / +183% |
| VCELVericel Corporation | 2.3 bn | 107.7 | 7.2% | 7.9% | +16.5% | +13% / +28% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -40.9% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -26.1% | -83.0% | −7.6% | +83% / +24% |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| FDMT4D Molecular Therapeutics, Inc. | 611.3 m | — | -43.3% | -194.7% | +230,194.6% | +14% / +6% |
| SRZNSurrozen, Inc. | 372.0 m | — | — | -2,885.3% | −67.4% | +91% / +340% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
1- and 3-year price returns: for FDMT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
4D Molecular Therapeutics is a late-stage biotechnology company developing genetic therapies built on proprietary AAV vectors, focused on 4D-150 for wet age-related macular degeneration and diabetic macular edema. It matters now because its Phase 3 program is underway with topline readouts expected in 2027, and it reported 430.6 mn USD in cash and equivalents at June 30, 2026 2.
SWOT
Strengths
- The proprietary vector platform and long-term clinical data from the PRISM study are cited strengths, alongside RMAT and PRIME designations for 4D-150 12.
- Rapid enrollment in 4FRONT-1 and completed enrollment in 4FRONT-2 point to strong interest from investigators and patients 2.
- The Otsuka partnership brings an upfront payment and future milestones, partially easing pressure on internal resources 2.
Weaknesses
- The company has no approved products and no product sales revenue, while net losses remain substantial 1.
- Reliance on external financing and credit facilities raises questions about long-term flexibility, and debt has increased with the credit facility 23.
- Concentration on one main product, 4D-150, makes Phase 3 results decisive for the whole company 1.
Opportunities
Threats
- A failure in the 4FRONT trials could compromise the whole portfolio and reduce investor and partner interest 2.
- Competition from other retinal AAV therapies and from longer-interval dosing alternatives could limit adoption 1.
- Macroeconomic conditions, including interest rates and tariffs, could make access to capital harder in the short term 2.
Risks
- Dependence on Phase 3 resultshigh
The entire strategy rests on 4D-150; the 4FRONT-1 and 4FRONT-2 readouts expected in 2027 could fundamentally change the company's outlook 12.
- Need for additional capitalhigh
The company states that current cash could fund operations into the second half of 2028, and without further financing it could scale back programs 23.
- Shareholder dilutionmedium
Equity issuances for financing could reduce the stake of existing shareholders, and debt covenants could limit flexibility 1.
- Dependence on partnersmedium
Otsuka leads regulatory and commercial activities in Asia-Pacific, so the company could lose control over certain decisions in that region 2.
- Safety riskslow
Intraocular inflammation and other adverse effects, though rare in the reported data, could affect approval or adoption of the product 12.
Investment thesis
What would need to be true (bull case)
- If Phase 3 results for wet AMD are favorable, 4D-150 could represent a paradigm shift in a very large market 12.
- The substantial reduction in injections reported in PRISM could support adoption by patients and physicians 2.
- The Otsuka partner and the expanded credit line could ease immediate capital pressure during Phase 3 trials 23.
What would break the thesis
- The company has no product revenue and losses keep growing, so any trial delay could extend the period without revenue 12.
- Dependence on financing and debt could limit strategic options if markets become more difficult 23.
- Confirmation of benefit in a Phase 3 trial is not assured, and the preliminary data come from small or non-randomized studies 12.
What to watch
- Topline 4FRONT-1 results for 4D-150 in wet AMDQ2 2027
- Topline 4FRONT-2 results for 4D-150 in wet AMDH2 2027
- Start of the Phase 3 trial in diabetic macular edemaQ3 2026
- Investor Day and update on the commercial plan for 4D-15021 October 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Revenue is modest and comes from collaboration agreements: in October 2025 Otsuka made an upfront payment of 85.0 mn USD for rights to 4D-150 in Asia-Pacific, while the company retains rights in the United States, Latin America and Europe 2. The net loss was 140.1 mn USD in fiscal 2025 and 72.9 mn USD in the second quarter of 2026 12.
The company has no products approved for sale and has not generated product sales revenue since inception; its funding depends on external sources, including a credit facility with Hercules Capital of up to 200 mn USD, of which 20 mn USD was initially drawn 3.
Segments
Market context
The branded market for anti-VEGF bolus therapies in retinal vascular diseases exceeds 16 bn USD, of which wet AMD and DME account for about 14 bn USD 1. Commercial potential depends on physician adoption of a backbone therapy that could reduce injections, given that about 40% of wet AMD patients discontinue treatment by year one 1.
Trends
- Treatment burden of frequent injectionstailwind
Patients with retinal vascular disease need repeated in-office injections, and treatment discontinuation can lead to vision loss; a one-time therapy could change the standard of care if confirmed in trials 1.
- Aging population and rising diabetestailwind
The prevalence of macular degeneration and diabetes is growing, which could expand the target market for retinal products 1.
- Cost of capital and volatile financial marketsheadwind
The company states that access to financing could be affected by rising interest rates, inflation and tariffs, and without additional capital it may have to reduce programs 2.
- Strategic partnerships as funding sourcemixed
The Otsuka agreement and Cystic Fibrosis Foundation funding show partnerships can bring resources, but may also involve ceding certain rights to partners 12.
Competitive position
Competition includes anti-VEGF bolus injection therapies, as well as other AAV approaches being developed by other companies for wet AMD, using subretinal, suprachoroidal or intravitreal delivery with mouse-evolved vectors 1. In cystic fibrosis, Vertex CFTR modulators are already approved and are the reference treatment for most patients 1.
The company differentiates on primate-evolved vectors, intravitreal in-office administration and simultaneous inhibition of four angiogenic targets, which it says distinguishes it from other AAV therapies in development 1.
- Vertex PharmaceuticalsVRTX
Company whose CFTR modulators were approved for cystic fibrosis and are considered an existing therapeutic alternative in the source filing 1.
- Otsuka Pharmaceutical
Partner holding exclusive rights to 4D-150 in Asia-Pacific and leading regulatory and commercial activities in that region 2.
- Developers of AAV therapies for wet AMD
Companies using conventional or mouse-evolved AAV vectors delivered subretinally, suprachoroidally or intravitreally, cited in the annual report 1.
- Producers of bolus anti-VEGF therapies
Repeated-injection anti-VEGF therapies form the current standard of care that the company intends to transform 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report28 Sept 2026Other events
- Quarterly report13 Aug 2026
- Current report13 Aug 2026Results of operations
- Current report20 Jul 2026Other events
- Current report29 Jun 2026Material agreement · Creation of a direct financial obligation
- Current report22 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement28 Apr 2026
- Current report30 Mar 2026Departure or appointment of officers
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / 4D Molecular Therapeutics, Inc. · 18 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / 4D Molecular Therapeutics, Inc. · 13 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / 4D Molecular Therapeutics, Inc. · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.